Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Assets for 10 consecutive years, with $951.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 16.4% to $951.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $951.0 million, a 16.4% increase, with the full-year FY2025 number at $951.0 million, up 16.4% from a year prior.
  • Current Assets was $951.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $643.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.1 billion in Q1 2021 to a low of $596.0 million in Q1 2024.
  • A 5-year average of $799.8 million and a median of $783.0 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 40.83% in 2023, then skyrocketed 37.39% in 2024.
  • Ultragenyx Pharmaceutical's Current Assets stood at $856.6 million in 2021, then grew by 3.19% to $883.9 million in 2022, then fell by 17.16% to $732.2 million in 2023, then rose by 11.58% to $817.0 million in 2024, then increased by 16.4% to $951.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Current Assets are $951.0 million (Q4 2025), $643.2 million (Q3 2025), and $719.8 million (Q2 2025).